Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.

NCT02012231 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

5

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma
Thyroid Cancer
Colorectal Cancer
Non-small Cell Lung Cancer
Cholangiocarcinoma
Histiocytosis
Hairy Cell Leukemia

Interventions

DRUG: PLX8394

Sponsor

Fore Biotherapeutics